United States Pen Needles Market

United States Pen Needles Market Size and Share:

The United States pen needles market size was valued at USD 916 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 2,444 Million by 2033, exhibiting a CAGR of 11.5% from 2025-2033. The market is majorly driven by the increasing prevalence of diabetes and other chronic conditions, rising awareness about effective diabetes management, the strong presence of major industry players, the growing adoption of insulin delivery devices, advancements in pen needle technology, and the expanding healthcare infrastructure.

The rising incidences of diabetes with a growing patient base that requires insulin delivery systems and the growing geriatric population are significantly driving the market growth. Another factor is the increasing consciousness concerning the need for effective diabetes control and the shift toward self-injection devices. Furthermore, the ease of use of pen needles due to their innovative designs, such as thinner, smaller, and more comfortable operation has improved patient compliance, thereby accelerating the growth of the market size. The rising healthcare costs and the trend towards the improvement of patient care are also acting as significant growth-inducing factors for the market. The growth in the market is also fueled by the rising prevalence of diseases among the masses that require chronic disease management solutions.

Another factor fueling the growth of the market is the rising prevalence of osteoporosis, especially in the women population. According to the data published by Healthline in November 2023, about 13.1% of American women aged 50-64 and 27.1% of women aged 65 years and above have osteoporosis. Also, the prevalence of osteoporosis is 3.3% in men between 50 and 64 years and 5.7% in men over 65 years. This is especially true since the treatment of osteoporosis involves mostly injectables, which encourages the use of efficient methods of injection like pen needles. Furthermore, the increasing number of patients opting for self-injections, as the geriatric population in the US is increasing, also stimulates the market growth. Moreover, the discussion on chronic disease management such as compliance of treatment in osteoporosis patients is also propelling the usage of pen needle devices since they are quite easy to use and comfortable for the patients.

United States Pen Needles Market Trends:

Expanding use of pen needles in managing non-diabetic conditions

The growing popularity of pen needles for obesity treatment has been a key trend driving the growth of the market. According to CDC figures for 2023, a substantial percentage of the American population weighs 20% or over, depending on the state in which they live. 23 states in the USA have adult obesity rates of higher than 35%. As obesity rates rise, an increasing number of individuals are prepared to undergo weight loss therapies, including injections. Pen needles are a straightforward and convenient approach to administer drugs used to treat obesity, such as GLP-1 receptor agonists. With the expanding trends of obesity, healthcare practitioners and individuals have resorted to injection therapy, thus strengthening the market.

Increasing production of injection devices

The growing production of injection devices is propelling the market. For instance, on March 21, 2024, BD (Becton, Dickinson and Company), one of the leading global medical technologies companies, announced its plans to increase its domestic production to support the US healthcare need for syringes. The company’s operations in Nebraska and Connecticut, dedicated to increasing the supply of syringes and pen needles, is in response to the increasing number of patients on injectable therapies, particularly in the treatment of diabetes and obesity-related conditions. BD’s enlargement of production has placed the company in a firm position to address the forecasted market inclinations. This in turn will lead the growth of the market and elevate the accessibility of critical injection devices to patients at all times, hence making the market stable and resilient.

Growing demand for safety-engineered pen needles

The increase in safety concerns of patients while administering injections has led to the rising use of safety-engineered pen needles. These devices are especially effective in the retraction of needles in home care environments as both healthcare providers and patients have a high preference for low-needlestick injury devices. The DropSafe Sicura, launched by HTL-Strefa Inc. in 2023 is an example of this trend, which incorporates a standard plastic needle with an automatic locking shield that engages after the use of the needle eliminating the need for a manual one. With regulatory authorities such as the FDA continually increasing the safety threshold, manufacturers are coming up with such innovations to meet both safety and user-friendliness aspects and this is a major factor driving the growth of the market. The market share of safety-engineered pen needles continues to grow steadily, driven by increasing emphasis on patient safety and compliance with regulatory standards.

United States Pen Needles Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States pen needles market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on type, needle length, therapy, mode of purchase, and end user.

Analysis by Type:

• Standard Pen Needles
• Safety Pen Needles
   

Standard pen needles are widely used for insulin delivery due to their cost-effectiveness and simplicity. While they provide basic functionality, they are less focused on safety features, making them more prone to needle-stick injuries, especially in home care settings.

Safety pen needles are increasingly preferred for their built-in safety features, such as automatic retraction or needle shielding, which reduce the risk of needlestick injuries. These needles enhance patient safety and are gaining traction due to regulatory standards and the growing emphasis on minimizing injection-related risks.

Analysis by Needle Length:

• 4mm
• 5mm
• 6mm
• 8mm
• 10mm
• 12mm
   

The 4mm needle is ideal for shorter injection depths, offering greater comfort and reducing the risk of deep injections. It is popular for children and patients with smaller body sizes, ensuring precise medication delivery and minimizing tissue damage.

The 5mm needle provides a balance between comfort and effective insulin delivery, commonly used for patients with moderate body types. It ensures proper subcutaneous delivery with minimal discomfort. Furthermore, the 6mm needle length is commonly used for insulin injections, providing sufficient depth for subcutaneous delivery without causing pain. It is suitable for patients of all age groups and body types.

Analysis by Therapy:

• Insulin
• GLP-1
• Growth Hormones
   

Insulin therapy is essential for managing diabetes and helping regulate blood sugar levels. It is commonly administered through injections using pen needles, with various types such as rapid-acting, long-acting, and premixed formulations tailored to individual needs.

GLP-1 (glucagon-like peptide-1) therapies are increasingly used to manage type 2 diabetes and obesity. These injectable medications work by enhancing insulin secretion and reducing appetite. Safety-engineered pen needles are crucial for these treatments, as they promote patient adherence.

Growth hormone therapies are used for treating conditions such as growth deficiencies in children and adults. These injections, often administered with pen needles, are designed for ease of use and require precise delivery to ensure effectiveness.

Analysis by Mode of Purchase:

• Retail
• Non-Retail
   

Retail purchases of pen needles typically occur at pharmacies or online platforms, offering patients the convenience of buying devices without a prescription in certain cases. This mode is popular for individuals who self-manage their conditions and seek easy access to necessary supplies.

Non-retail purchases primarily involve bulk procurement through healthcare providers, hospitals, or clinics. These purchases are often made by organizations or healthcare professionals to ensure a consistent supply of pen needles for patient care, especially in institutional settings.

Analysis by End User:

• Hospitals and Clinics
• Home Healthcare
• Others
   

Hospitals and clinics are significant end users of pen needles, as they provide essential care for patients managing chronic conditions like diabetes. Pen needles are used for insulin delivery, GLP-1 therapies, and growth hormones. Healthcare facilities prioritize safety and efficiency, using safety-engineered needles to reduce risks during injections.

The home healthcare segment is witnessing substantial growth, as more patients are managing chronic conditions like diabetes and obesity at home. Pen needles are essential for self-injection, providing convenience and comfort for patients. The trend towards safety-engineered needles ensures better patient compliance, reducing the risk of needle-stick injuries and improving overall care.

Regional Analysis:

• Northeast
• Midwest
• South
• West
   

The Northeast region of the U.S. has a high concentration of healthcare facilities and a large aging population, contributing to the increased demand for pen needles. The region’s advanced healthcare infrastructure drives the adoption of safety-engineered pen needles, especially in hospitals, clinics, and home care settings, supporting market growth.

The Midwest region experiences steady growth in the pen needles market due to an expanding diabetic population and increasing healthcare awareness. With a strong presence of healthcare providers and pharmaceutical companies, there is a rising demand for affordable, reliable pen needle solutions, especially in rural areas and long-term care facilities.

The South regional market, which is characterized by its large elderly population and high rates of diabetes, is witnessing a growing demand for pen needles. Healthcare providers and home care services are adopting safety-engineered pen needles to improve patient safety, enhancing accessibility and adherence to treatment regimens in both urban and rural areas.

The West region leads in innovation and technology adoption, contributing significantly to the growth of the pen needles market. With a focus on patient-centric care and the growing prevalence of diabetes and obesity, the demand for advanced pen needle solutions, including safety-engineered devices, is increasing, particularly in metropolitan areas.

Competitive Landscape:

Key players in the United States pen needles market are driving growth through product innovation, technological advancements, and strategic partnerships. Several companies are introducing a wide range of pen needle solutions, including safety and standard needles, catering to the growing demand for diabetic care. The market is particularly witnessing an uptick in the adoption of safety pen needles, which are expected to be the fastest-growing segment due to their emphasis on reducing needlestick injuries. Additionally, these players are capitalizing on favorable reimbursement policies, which make pen needles more accessible, thereby enhancing patient adherence and improving clinical outcomes. Furthermore, collaborations between key players and healthcare providers are increasing market reach, making these products more available in both clinical and homecare settings.

The report provides a comprehensive analysis of the competitive landscape in the United States pen needles market with detailed profiles of all major companies.

Latest News and Developments:

• August 5, 2024: MTD Group announced the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems divisions. This strategic move is expected to significantly enhance MTD’s production capabilities, increasing its output to more than 2.5 billion units. The acquisition will likely strengthen MTD’s position in the healthcare market, particularly in the diabetes care and management sector, as it expands its product portfolio and manufacturing capacity.
• April 17, 2024: HTL-Strefa, a member of the MTD Group, announced important updates regarding its Droplet Micron 34G x 3.5mm pen needle. The device has recently received expanded approval from the U.S. Food and Drug Administration (FDA), which broadens its range of indications and shifts its status from prescription-only to over-the-counter availability. This approval is expected to benefit patients, as they will now be able to use the thinnest and shortest pen needle available in the U.S. to administer medications beyond insulin.

United States Pen Needles Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States pen needles market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the United States pen needles market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States pen needles industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.